Aleksandr Gintsburg, Director of the Gamaleya Research Institute of Epidemiology and Microbiology announced that a Russian cancer vaccine could enter clinical practice in one and a half to two years. This was said on the margins of the 27th St. Petersburg International Economic Forum (SPIEF) on Friday.
"The first vaccines - prototype vaccines - have been created to fight against melanoma, which is the most malignant and severe cancer type. Using a mouse melanoma model, three vaccine types, which have been created with the use of this technology, proved to protect these animals from dying. <...> The next stage, which we plan to launch in the beginning of the next year is, of course, the transfer of this technology to patients, but not in terms of starting mass treatment, but in terms of starting trials for these drugs in two of our leading oncology centres, and in reality let's hope that all this will enter clinical practice in a year and a half or two years," the microbiologist noted.
According to Gintsburg, specialists are working on a single technology to create unique drugs for each type of cancer.
"This vaccine, let me use a somewhat vulgar term, it pits our immune system, the patient's immune system, against malignant tumours, malignant cells, because this vaccine carries in its composition those changes that are characteristic at the genetic level of the tumour for a particular patient. As a result, the patient's immune system recognises both: the cells that have been hit by the vaccine and the cancer cells and starts to destroy them," Gintsburg added.
Earlier, Russian President Vladimir Putin stated that Russian specialists have come close to creating vaccines against cancer.
SPIEF 2024, taking place from June 5-8, includes participants from over 136 countries. Since its inception in 1997, the forum has served as a platform for international dialogue on economic matters, with the patronage and participation of the Russian Federation's president since 2005.
Cancer vaccination 'will enter clinical practice in 1.5-2 years' - Russian academic Gintsburg
Aleksandr Gintsburg, Director of the Gamaleya Research Institute of Epidemiology and Microbiology announced that a Russian cancer vaccine could enter clinical practice in one and a half to two years. This was said on the margins of the 27th St. Petersburg International Economic Forum (SPIEF) on Friday.
"The first vaccines - prototype vaccines - have been created to fight against melanoma, which is the most malignant and severe cancer type. Using a mouse melanoma model, three vaccine types, which have been created with the use of this technology, proved to protect these animals from dying. <...> The next stage, which we plan to launch in the beginning of the next year is, of course, the transfer of this technology to patients, but not in terms of starting mass treatment, but in terms of starting trials for these drugs in two of our leading oncology centres, and in reality let's hope that all this will enter clinical practice in a year and a half or two years," the microbiologist noted.
According to Gintsburg, specialists are working on a single technology to create unique drugs for each type of cancer.
"This vaccine, let me use a somewhat vulgar term, it pits our immune system, the patient's immune system, against malignant tumours, malignant cells, because this vaccine carries in its composition those changes that are characteristic at the genetic level of the tumour for a particular patient. As a result, the patient's immune system recognises both: the cells that have been hit by the vaccine and the cancer cells and starts to destroy them," Gintsburg added.
Earlier, Russian President Vladimir Putin stated that Russian specialists have come close to creating vaccines against cancer.
SPIEF 2024, taking place from June 5-8, includes participants from over 136 countries. Since its inception in 1997, the forum has served as a platform for international dialogue on economic matters, with the patronage and participation of the Russian Federation's president since 2005.
Aleksandr Gintsburg, Director of the Gamaleya Research Institute of Epidemiology and Microbiology announced that a Russian cancer vaccine could enter clinical practice in one and a half to two years. This was said on the margins of the 27th St. Petersburg International Economic Forum (SPIEF) on Friday.
"The first vaccines - prototype vaccines - have been created to fight against melanoma, which is the most malignant and severe cancer type. Using a mouse melanoma model, three vaccine types, which have been created with the use of this technology, proved to protect these animals from dying. <...> The next stage, which we plan to launch in the beginning of the next year is, of course, the transfer of this technology to patients, but not in terms of starting mass treatment, but in terms of starting trials for these drugs in two of our leading oncology centres, and in reality let's hope that all this will enter clinical practice in a year and a half or two years," the microbiologist noted.
According to Gintsburg, specialists are working on a single technology to create unique drugs for each type of cancer.
"This vaccine, let me use a somewhat vulgar term, it pits our immune system, the patient's immune system, against malignant tumours, malignant cells, because this vaccine carries in its composition those changes that are characteristic at the genetic level of the tumour for a particular patient. As a result, the patient's immune system recognises both: the cells that have been hit by the vaccine and the cancer cells and starts to destroy them," Gintsburg added.
Earlier, Russian President Vladimir Putin stated that Russian specialists have come close to creating vaccines against cancer.
SPIEF 2024, taking place from June 5-8, includes participants from over 136 countries. Since its inception in 1997, the forum has served as a platform for international dialogue on economic matters, with the patronage and participation of the Russian Federation's president since 2005.